Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

October 4, 2022

https://www.globenewswire.com/news-release/2022/10/04/2527776/32920/en/Exagen-Announces-Appointment-of-Andrew-L-Concoff-MD-FACR-CAQSM-as-Chief-Innovation-Officer.html

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq:XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis medical initiatives, including the AVISE® RADR platform (Rheumatoid Arthritis Drug Response). Dr. Concoff will be a key principal in strategy, business development, portfolio management, pipeline prioritization, and formation of new business ventures, as well as the advancement of innovative access partnerships with payors and governments globally.

Read more at globenewswire.com

Related news for (XGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.